Corcept Therapeutics Inc. (NASDAQ:CORT) Director Patrick G. Enright sold 36,941 shares of the firm’s stock in a transaction dated Friday, November 25th. The stock was sold at an average price of $9.34, for a total transaction of $345,028.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.18 on Friday. The stock’s 50 day moving average is $7.78 and its 200 day moving average is $6.22. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of 235.38 and a beta of 1.64. Corcept Therapeutics Inc. has a 12-month low of $3.22 and a 12-month high of $10.00.
Hedge funds have recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in Corcept Therapeutics during the second quarter worth $100,000. Gotham Asset Management LLC increased its stake in Corcept Therapeutics by 39.2% in the third quarter. Gotham Asset Management LLC now owns 20,908 shares of the company’s stock worth $136,000 after buying an additional 5,884 shares during the period. Campbell & CO Investment Adviser LLC increased its stake in Corcept Therapeutics by 35.8% in the third quarter. Campbell & CO Investment Adviser LLC now owns 21,446 shares of the company’s stock worth $139,000 after buying an additional 5,652 shares during the period. Prudential Financial Inc. acquired a new stake in Corcept Therapeutics during the third quarter worth $141,000. Finally, BlackRock Group LTD increased its stake in Corcept Therapeutics by 5.1% in the third quarter. BlackRock Group LTD now owns 22,573 shares of the company’s stock worth $147,000 after buying an additional 1,089 shares during the period. Hedge funds and other institutional investors own 41.24% of the company’s stock.
Several analysts have commented on CORT shares. FBR & Co restated a “buy” rating on shares of Corcept Therapeutics in a report on Thursday, August 4th. Zacks Investment Research lowered shares of Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 4th. Finally, Piper Jaffray Cos. set a $12.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 19th.
Corcept Therapeutics Company Profile